Company Profile

Enbiotix Inc
Profile last edited on: 1/21/2022      CAGE: 70CA2      UEI: DMFLG44ZFLL9

Business Identifier: Transforming /revitalizing existing antibiotic classes to combat rise in drug-resistant bacterial infections
Year Founded
2012
First Award
2016
Latest Award
2016
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

197 West Springfield Street
Boston, MA 02118
   (508) 400-1856
   info@enbiotix.com
   www.enbiotix.com
Location: Single
Congr. District: 07
County: Suffolk

Public Profile

In December 2021 it was announced that Swiss firm Polyphor - structured around discovery and development of macrocycle drugs addressing high unmet medical needs - had merged with EnBiotix with the new entity renamed Spexis. With limited SBIR involvement, Boston-based Enbiotix since 2013 had functioned as an engineered antibiotics company deploying novel systems and synthetic biology technologies developed by Prof. James J. Collins, the Termeer Professor of Medical Engineering & Science Professor, Department of Biological Engineering, MIT. These technologies enable the development of both novel antibiotics and potentiators of existing antibiotics having the potential to transform their spectrum of activity and resistance profile. With drug-resistant and drug-tolerant infections rapidly becoming a global health crisis, EnBiotixÂ’s robust product pipeline had addressed a wide range of acute and chronic infections to significantly impact the lives of patients.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Key People / Management

  Jeffrey D Wager -- Chairman & CEO

  James J Collins -- Scientific Founder

  Michael Garrett -- Chief Business Officer

  Diane Joseph-Mccarthy -- Vice President, Translational Science

  Benjamin Perrone -- Business Development Manager

  Jeffrey A Radding -- Vice President Biology